Immunome Inc.
IMNM
Dennis H. Giesing
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Dennis H. Giesing
Immunome Inc. reported in an 8-K filed October 4, 2023 that Dennis H. Giesing was terminated as Immunome's former Chief Development Officer, effective October 2, 2023. The proxy statement of Immunome Inc. reports total compensation of $3,499,917 for Dennis H. Giesing in fiscal 2021, including a base salary of $306,971.
“(iii) Dennis Giesing, Ph.D., Immunome's former Chief Development Officer, was terminated as an officer and employee of Immunome effective as of the closing of the Merger.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Immunome Inc. (IMNM)
Proxy statement
Start not stated–2023-10-02
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2021 | Immunome Inc. (IMNM) | Chief Development Officer | $306,971 | $3,499,917 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.